Synaptogenix Inc (SNPX)

[Cyosol]

Not only has Dr. Alkon confirmed that Bryostatin 1 can be used for AD patients across the spectrum (even the early dementia cases that haven't turned into full-blown AD yet), but that low-cost test you're thinking about exists already and is currently being developed by Neurotrope (although it looks like they're more focused on AD trials right now and will wait with the diagnostic test until later).

Dr. Alkons research shows how PKCe levels can be measured in the skin, and how the levels directly correlate with the probability of getting AD in the future.

These two articles show how it can be done:

https://www.researchgate.net/publication/263934332_Fibroblast_Aggregation_Rate_Converges_with_Validated_Peripheral_Biomarkers_for_Alzheimer%27s_Disease

https://www.researchgate.net/publication/230657221_Spatiotemporal_Complexity_of_Fibroblast_Networks_Screens_for_Alzheimer%27s_Disease

The abstract for that first one has a particularly interesting part in it:

"Furthermore, we show that by using a simple majority rule, i.e., two out of the three assays have the same outcome, we significantly increase the agreement with clinical AD diagnosis (100%). Based on the high accuracy of this strategy, the biomarker profile appears to accurately identify AD patients for therapeutic intervention."